Category Archives: Health

Latest From Health

Wall Street Journal: The Assault on Drug Innovation


Today, the Wall Street Journal published an editorial commenting on yesterday’s proposed plan by Secretary Hillary Clinton’s campaign to dramatically increase intrusive government regulation of our industry. BIO shared many of the concerns raised by this editorial, concerns which were noted in our statement yesterday. To put into perspective the potential consequences of that proposal, the editorial noted as an example that “Inside of a decade or two, metastatic cancer may become a chronic condition and chemotherapy a relic.” Breakthroughs Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO Statement on Patient Access to Medicines

“As a general policy, BIO does not comment on matters related to individual company products or product pricing decisions, such as today’s news about Turing Pharmaceuticals. That said, the focus of the biotechnology industry is to develop innovative therapies and cures for patients. This means it is imperative not only that we develop these new medicines, but that all patients have access to them, as necessary to meet their healthcare needs. This principle should apply Read More >

Health  |  Leave a comment  |  Email This Post

Reality Check for AHIP: Competition Driving Down Costs for Hepatitis C Meds


Yesterday at a House Judiciary Committee hearing on competition in the healthcare marketplace, AHIP Executive Vice President Daniel Durham took the occasion to bemoan what he termed “monopoly pricing” in the pharmaceutical industry. He proceeded to cite the cost of two new specialty medicines for Hepatitis C, Gilead Sciences’ Sovaldi and Harvoni, as a “case study” of that problematic monopoly pricing. Durham’s analysis suffers from a particularly egregious flaw: Gilead and its products do not enjoy Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO Statement: Institute for Clinical and Economic Review Framework


This week, the Institute for Clinical and Economic Review (ICER) released its Value Assessment Framework. While we welcome a robust discussion on the value of treatments and cures, we have concerns with ICER’s methodology, which has not been validated, and preliminary conclusions which underestimate the value of innovative new medicines. We believe that the most important priority is to empower patients with information that will be helpful in clinical decision-making with their healthcare providers, and Read More >

Health  |  Leave a comment  |  Email This Post

Health Affairs Study: Want to save money in Medicaid? Increase adherence.

Health Affairs

At BIO, we have long argued that the use of prescription medicines can yield substantial savings to other areas of the healthcare system by reducing costly hospitalizations, surgeries, visits to the emergency room and other non-drug drivers of health spending. A study published in Health Affairs this week further bolstered that point and quantified the potential savings that Medicaid could realize from better prescription drug adherence among beneficiaries. The authors found that increasing the number Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,